Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
Chong Ma, Jing Feng, Rahnuma Wahid et al.
✦ AI-curated · Sources linked
In 30 seconds
The Phase 3 NextCOVE trial evaluated the immune correlates of the mRNA-1283 COVID-19 vaccine in over 10,000 participants aged ≥12 years. The study found that higher neutralizing antibody (nAb) levels on Day 29 were associated with lower COVID-19 risk and higher relative vaccine efficacy compared to mRNA-1273. Notably, the estimated hazard ratios for nAb levels against variants were significantly lower, indicating strong protection.
Key findings
- Higher Day 29 nAb levels were associated with lower COVID-19 risk across multiple variants.
- The estimated hazard ratio for nAbs against D614G was 0.70 (95% CI: 0.48-1.02; p = .064).
- For BA.4/BA.5, the hazard ratio was 0.49 (95% CI: 0.41-0.58; p < .001).
- Against XBB.1.5, the hazard ratio was 0.41 (95% CI: 0.35-0.49; p < .001).
Why it matters
Understanding the relationship between neutralizing antibody levels and COVID-19 risk is crucial for evaluating vaccine efficacy, especially as new variants emerge. This study reinforces the importance of monitoring nAb levels as potential correlates of protection.